However, Nrf2 activators, bardoxolone and L-sulforaphane, blocked the formation of angiotensin II-induced ROS, resulting in restored endothelial dysfunction and decreased inflammation in both WKY and SHRSP cells. Here, AGT is linked to endothelial dysfunction.